The breadth and diversity of dermatology, the speed at which our understanding of skin pathophysiology has improved, and the introduction of new therapies combine to make this field interesting and challenging. The expanding scope of our specialty also creates a broad range of educational needs for practicing clinicians.
Skin Disease Education Foundation’s 39th Hawaii Dermatology Seminar offers updates from experts addressing a broad range of skin diseases, and covers advances in both medical and aesthetic dermatology. The articles in this educational supplement summarize the highlights of clinical sessions presented during the CME/CE conference by leading experts in the field of dermatology.
Tumor necrosis factor (TNF) inhibitors are the cornerstone of treatment for psoriasis, but choice of agent can be confusing. This supplement includes a comparison of the TNF inhibitors approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis. Psoriasis has been linked to an elevated risk of several comorbidities. Can choice of psoriasis therapy alleviate any of these conditions? Our faculty evaluates how risk or presence of comorbid conditions might inform the choice of psoriasis therapy, and whether control of psoriasis can alleviate any coexisting conditions.
Accumulating evidence suggests that rosacea, like psoriasis, is a disorder of the immune system – specifically, of innate rather than adaptive immunity. This CME/CE supplement summarizes those findings. It also reviews studies of new therapies for this condition, as well as new evidence validating the use of a commonly prescribed agent.
Method of Participation
Participants should view the activity information, view the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test you will be directed to a webpage that will allow you to receive your certificate of credit via email.
Statement of Need
The growing body of evidence about the pathophysiology of skin diseases has broadened our understanding of these diverse conditions, as well as their effects on other aspects of health and quality of life. Psoriasis is an inflammatory disease that increases the risk of many other conditions. The provider managing the patient’s psoriasis must consider these potential and actual comorbidities when choosing psoriasis therapy and monitoring patients. The range of anti-tumor necrosis factor agents and other treatments for psoriasis increases the opportunity to tailor therapy to the patient’s responses, characteristics, comorbidities if any, and preferences.
Studies have shed light on the immune system underpinnings of rosacea in recent years, and new therapies have received US Food and Drug Administration approval for treatment of this condition.
Clinicians also are called upon to review and understand nonsurgical facial rejuvenation including correct injection techniques in the use of filler and toxins.
After completing this activity, participants should be better able to:
- Differentiate the characteristics of the tumor necrosis factor (TNF) inhibitors approved for use in treating psoriasis and apply that information to clinical practice.
- Integrate new therapies for rosacea into practice and describe current theories about rosacea pathophysiology.
- Determine the appropriate nonsurgical techniques for facial rejuvenation.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Rutgers, The State University of New Jersey, and Global Academy for Medical Education LLC. Rutgers, The State University of New Jersey, is accredited by the ACCME to provide continuing medical education for physicians.
Rutgers, The State University of New Jersey, designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Rutgers, The State University, Center for Continuing and Outreach Education is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number P173-5/31/2016.
This activity is awarded 2.77 contact hours (60 minute CH).
Nurses should only claim those contact hours actually spent participating in the activity.
In accordance with the disclosure policies of Rutgers and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants:
- the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and
- the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Kristina Callis Duffin, MD, MS, Grant/Research: AbbVie Inc., Amgen Inc., Bristol- Myers Squibb Company, Eli Lilly and Company, Janssen Biotech, Inc, and Pfizer Inc.; Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis Pharmaceuticals Inc., Pfizer, and XenoPort Inc.; Advisory Board: Eli Lilly and Janssen. Scientific Advisory Board: Eli Lilly and Janssen.
Suzanne L. Kilmer, MD, Grant/Research Support: Allergan, Candela-Syneron, Cynosure, Lumenis, Living Proof, Miramar Labs, Solta, Valeant, and Zeltiq Aesthetics. Scientific Advisory Board: Allergan, Syneron, Living Proof, Lumenis, Miramar, Zeltiq. Scientific Advisory Board Syneron, Allergan, Living Proof, Lumenis, Miramar, and Zeltiq
Craig L. Leonardi, MD, Grant/Research: AbbVie, Amgen, Anacor, Celgene, Coherus BioSciences, Eli Lilly, Galderma Laboratories, L.P., Janssen, LEO Pharma, Maruho, Merck, Novartis, Novo Nordisk, Pfizer, Sandoz Inc., Stiefel, Tolmar, Warner Chilcott, and Wyeth. Consultant: AbbVie, Amgen,Boehringer-Ingelheim Dermira, Eli Lilly, Janssen, LEO, Pfizer, Sandoz, and UCB, Inc. Speakers Bureau: AbbVie.
Mark G. Rubin, MD, Consultant: Allergan and Merz.
Roberta Senglemann, MD, FAAD Consultant: Allergan and Merz. Scientific Advisory Board: Allergan and Merz
Jerry K. L. Tan, MD, FRCPC, Grant/Research: AbbVie, Allergan, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Pfizer, and Valeant; Consultant: Galderma and Sandoz. Advisory Cipher Pharmaceuticals, Galderma, GlaxoSmithKline Pharmaceutical Company, Sandoz, Stiefel, and Valeant; Speakers Bureau: Cipher Pharmaceuticals, Galderma, Pierre-Fabre, and Valeant.
Peer Review Statement
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a nonconflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content, and balance of presentation by: Claudia Carron, MSN, RN, Department of Dermatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Ms Carron has no relevant financial relationships to disclose.
Field Testers: This activity was pilot-tested for time required by: Physicians Brian Lee, MD, Rosalind Julius Mickel, RN, MSN, Shreya Patel, MD, Sima Patel, MD, Nurses- Geraldine Bocchieri, RN, BSN and Carol Ruland, RN. The field testers have no relevant financial relationships to disclose.
CCOE Staff: Tristan Nelsen, MNM, CMP, and Elizabeth Ward, MSJ, have no relevant financial relationships to disclose.
Global Academy for Medical Education Staff: Sylvia H. Reitman, MBA, DipEd; Shirley V. Jones, MBA; and Joanne Still, BA have no relevant financial relationships to disclose.
Off Label/Investigational-Use Disclosure
This activity discusses the off-label use of the following approved agents: adalimumab, cyclosporine ophthalmic emulsion, doxycycline, etanercept, fluconazole, isotretinoin, itraconazole, ketoconazole, methotrexate, minocycline (oral and foam), secukinumab, ustekinumab, and tumor necrosis factor inhibitors as a class. This continuing education activity was developed from faculty presentations at Skin Disease Education Foundation’s 39th Annual Hawaii Dermatology Seminar, held March 1-6, 2015, in Kauai, Hawaii. The Faculty acknowledge the editorial assistance of Global Academy for Medical in the development of this activity. The ideas and opinions expressed in this activity are those of the speakers and do not necessarily reflect the views of the supporters, Global Academy for Medical Education, Rutgers, or the Publisher.
Provider Contact Information
Please direct content or CE related questions or concerns to CCOE at 973-972-4267 or email [email protected].
Contact Information for Technical Questions
Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email [email protected].
Copyright © 2016 by Global Academy for Medical Education, LLC, and its Licensors. All rights reserved. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher. Global Academy for Medical Education, LLC will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this activity, including any claims related to the products, drugs, or services mentioned herein. Developed in the United States of America.
Course Viewing Requirements
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of nonprofit or government organizations and non–health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Roger I. Ceilley, MD, Consultant: Ferndale Pharma Group, Inc, DUSA Pharmaceuticals, Inc., LEO Pharma Inc., Valeant Pharmaceuticals North America LLC, Xoft Inc.; Speakers Bureau: DUSA and LEO Pharma; Advisory Board: Ferndale, DUSA, Xoft Inc.
Kristina Callis Duffin, MD, MS, Grant/Research: AbbVie Inc., Amgen Inc., Bristol- Myers Squibb Company, Eli Lilly and Company, Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Stiefel Laboratories, Inc., and XenoPort, Inc.; Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and XenoPort; Advisory Board: Eli Lilly and Janssen.
Joseph F. Fowler, Jr, MD, Grant/Research: AbbVie, Allergan, Inc., Amgen, Anacor Pharmaceuticals, Inc., Celgene Corporation, Chugai Pharma USA LLC, Eli Lilly, Galderma Laboratories, L.P., Genentech Inc, Janssen, Johnson & Johnson, Merck & Co., Inc., Novartis, Onset Dermatologics LLC, Pfizer, Regeneron Pharmaceuticals, Inc, SmartPractice Dermatology/Allergy, Taisho Pharmaceutical Co., Taro Pharmaceutical Industries Ltd, and Valeant; Consultant: Bayer Healthcare, Galderma, Johnson & Johnson, Medimetriks Pharmaceuticals Inc, Ranbaxy Laboratories Limited, and SmartPractice; Speakers Bureau: Galderma, SmartPractice, and Valeant.
Kenneth B. Gordon, MD, Grant/Research: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer; Consultant: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer.
Linda F. Stein Gold, MD, Consultant: Allergan, Anacor Pharmaceuticals, Celgene, Eli Lilly, Galderma, LEO Pharma, Novartis, and Valeant; Speakers Bureau: Celgene, Galderma, LEO Pharma, Novartis, Taro, and Valeant; Advisory Board: Allergan, Anacor Pharmaceuticals, Celgene, Eli Lilly, Galderma, LEO Pharma, Novartis, Promius Pharma, LLC, and Valeant; Medical Legal Advisor: Hoffmann- La Roche Inc.
Jerry K. L. Tan, MD, FRCPC, Grant/Research: Allergan, Bayer, Cipher Pharmaceuticals Inc, Dermira, Galderma, and Valeant; Consultant: Cipher Pharmaceuticals, Galderma, GlaxoSmithKline Pharmaceutical Company, Hoffmann-La Roche, Stiefel, and Valeant; Speakers Bureau: Cipher Pharmaceuticals, Galderma, Pierre-Fabre, and Valeant.
Christopher B. Zachary, MBBS, FRCP, Consultant: Cutera, Inc. and ZELTIQ Aesthetics, Inc.; Speakers Bureau: Cynosure, Inc. and Solta Medical, a division of Valeant; Advisory Board: ZELTIQ.